Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Agenus Inc
(NQ:
AGEN
)
5.630
-0.240 (-4.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Agenus Inc
< Previous
1
2
3
Next >
Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer
March 27, 2023
From
Agenus Inc.
Via
Business Wire
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
March 14, 2023
From
Agenus Inc.
Via
GlobeNewswire
Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
March 12, 2023
Conference Call Cancelled
From
Agenus Inc.
Via
GlobeNewswire
Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
March 11, 2023
Conference Call on Monday, March 13, 2023 at 8:30 a.m. ET
From
Agenus Inc.
Via
GlobeNewswire
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
February 28, 2023
Conference Call on Tuesday, March 14, 2023 at 8:30 a.m. ET
From
Agenus Inc.
Via
GlobeNewswire
Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer
February 28, 2023
From
Agenus Inc.
Via
GlobeNewswire
Agenus to Participate in February Investor Conferences
January 26, 2023
From
Agenus Inc.
Via
GlobeNewswire
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
January 23, 2023
From
Agenus Inc.
Via
GlobeNewswire
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference
January 10, 2023
From
Agenus Inc.
Via
GlobeNewswire
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
December 21, 2022
From
Agenus Inc.
Via
GlobeNewswire
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma
November 17, 2022
From
Agenus Inc.
Via
GlobeNewswire
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
November 16, 2022
From
Agenus Inc.
Via
GlobeNewswire
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers
November 14, 2022
From
Agenus Inc.
Via
GlobeNewswire
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
November 08, 2022
From
Agenus Inc.
Via
GlobeNewswire
Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report
October 25, 2022
From
Agenus Inc.
Via
GlobeNewswire
GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
October 13, 2022
From
Agenus Inc.
Via
GlobeNewswire
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
October 12, 2022
From
Agenus Inc.
Via
GlobeNewswire
Agenus to Host “The Road Taken” R&D Event on November 12, 2022
October 05, 2022
From
Agenus Inc.
Via
GlobeNewswire
Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 05, 2022
From
Agenus Inc.
Via
GlobeNewswire
Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report
July 27, 2022
Conference Call on Tuesday, August 9, 2022 at 8:30 a.m. ET
From
Agenus Inc.
Via
GlobeNewswire
Why ‘Killer’ T Cells Could Boost COVID Immunity In Face Of New Variants
May 20, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
May 18, 2021
From
Bristol-Myers Squibb
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.